埃克替尼治疗表皮生长因子受体敏感突变的晚期非小细胞肺癌获益患者的临床分析

Abstract
Figure/Table
References (17)
Related Citation (5)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore clinical effect ofⅠcotinib in treatment of epidermal growth factor receptor(EGFR) sensitive mutations in patients with advanced non-small cell lung cancer benefit.Methods 68 patients of EGFR sensitive mutations with advanced non-small cell lung cancer benefit in our hospital from January 2013 to December 2014 were selected and randomly divided into two groups by using single and double number,34 cases in each group.Group A were givenⅠcotinib treatment,patients in group B were were given Gefitinib treatment,overall effective rate,benefit rate,physical status score and incidence of adverse reactions in two groups were compared and observed.Results Overall effective rate was 82.4%in group A,with 76.5%in group B,and the difference was statistically significant(P＜0.05); 1 year benefit rate and physical status score in group A were slightly better than those in group B,and the difference was not statistically significant(P＞0.05),2 years benefit rate was similar between two groups and had no statistical difference(P＞0.05);incidence of adverse reactions in group A were lower than those in group B(P＜0.05).ConclusionⅠcotinib in treatment of EGFR sensitive mutation in patients with advanced non-small cell lung cancer has significant effect,and less adverse reactions,it is worthy of clinical promotion.

Key words： Ⅰcotinib EGFR mutation Advanced non-small cell lung cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SUN Yong

Cite this article:

SUN Yong. Clinical analysis of Icotinib in treatment of epidermal growth factor receptor sensitive mutations in advanced non small cell lung cancer benefit[J]. 中国当代医药, 2016, 23(30): 59-61.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I30/59

[1]	农靖颖，秦娜，王敬慧，等.盐酸埃克替尼治疗晚期复发非小细胞肺癌的临床疗效[J].中国肺癌杂志，2013，16（5）：247-250.
[2]	宋正波，余新民，蔡菊芬，等.埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析[J].中国肺癌杂志，2013，16（3）：138-143.
[3]	庞林荣，陈俊，黄佳，等.盐酸埃克替尼治疗晚期非小细胞肺癌的临床研究[J].浙江医学，2015，37（20）：1668-1673.
[4]	苏晓妹，刘桢，朱亚杰，等.盐酸埃克替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌的疗效观察[J].中国全科医学，2013，16（39）：3967-3969.
[5]	李曦，杨新杰，孙怡芬，等.盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察[J].中华肿瘤杂志，2012，34（8）：116-119.
[6]	郭磊，李爱洁，王键玮，等.盐酸埃克替尼治疗晚期肺腺癌的回顾性研究[J].中国药物应用与监测，2015，12（2）：69-72.
[7]	何昊，杨镇洲，李钱，等.EGFR-TKⅠs一线治疗EGFR敏感突变非小细胞肺癌患者的预后分析[J].第三军医大学学报，2016，38（7）：761-765.
[8]	蒋小雯，王文娴，张沂平.埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析[J].中国肺癌杂志，2016，19（4）：200-206.
[9]	林动，许凌，林景辉，等.埃克替尼一线治疗EGFR敏感性突变的晚期非小细胞肺癌的疗效观察[J].实用肿瘤杂志，2015，30（3）：220-224.
[10]	熊燃，许瑞彬.晚期非小细胞肺癌外科治疗的现状及进展[J].中国当代医药，2014，21（16）：194-196.
[11]	康倩，余正.EGFR-TKⅠs类药物治疗晚期非小细胞肺癌的药物经济学评价[J].中国药物评价，2013，30（5）：305-308.
[12]	曹京旭，李韧，俞立权，等.晚期非小细胞肺癌EGFR敏感突变型患者酪氨酸激酶抑制药的疗效和安全性[J].武警医学，2015，26（10）：988-990.
[13]	孙鹏，张阳，孙秀华，等.埃克替尼治疗33例晚期非小细胞肺癌的临床分析[J].大连医科大学学报，2014，36（1）：39-43.
[14]	李真斌，陈轩，汤晓梅，等.同步放化疗治疗非小细胞肺癌的临床分析[J].中国当代医药，2014，21（13）：23-25.
[15]	李曦，秦娜，王敬慧，等.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察[J].中国肺癌杂志，2015，18（12）：734-739.
[16]	石安辉，朱广迎.局部晚期非小细胞肺癌放化疗的现状与进展[J].临床外科杂志，2016，24（7）：505-508.
[17]	孙婧，陈晓峰，吴昊，等.盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察[J].中国现代医生，2014，52（36）：116-119.